Cell Therapy

begins with


Aspen Neuroscience leverages stem cell biology and genomics for Parkinson disease.

We are the leading company providing a personalized cell therapy with the aim to safely turn the clock back on Parkinson’s disease.

We are leveraging our in-house stem cell biology and genomics platform to provide the world’s first autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy for Parkinson’s Disease.


News & Media

Investor Relations


About Us Aspen


Find out about our organization,mission, our leadership team, our board of directors and scientific advisors.


We are developing autologous IPSC-derived cell replacement therapies, including autologous neuron therapies to help treat both idiopathic and genetically linked forms of Parkinson’s disease.

Aspen NeuronIllustration

Please note that we at Aspen Neuroscience do not make determinations on who would be eligible for participation in clinical trials, and we do not offer tours of our laboratory. At this time, our therapy has not yet been used in humans and clinical trials have not begun.